Assembly Biosciences, Inc. (ASMB)
NASDAQ: ASMB · Real-Time Price · USD
9.39
-0.17 (-1.78%)
Apr 1, 2025, 4:00 PM EDT - Market closed
Assembly Biosciences Revenue
In the year 2024, Assembly Biosciences had annual revenue of $28.52M with 298.16% growth. Assembly Biosciences had revenue of $7.36M in the quarter ending December 31, 2024, with 2.71% growth.
Revenue (ttm)
$28.52M
Revenue Growth
+298.16%
P/S Ratio
2.01
Revenue / Employee
$390,685
Employees
73
Market Cap
70.46M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
ASMB News
- 12 days ago - Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights - GlobeNewsWire
- 4 weeks ago - Assembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus - GlobeNewsWire
- 5 weeks ago - Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor ABI-1179 in Development for Recurrent Genital Herpes - GlobeNewsWire
- 3 months ago - Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B - GlobeNewsWire
- 9 months ago - Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inhibitors at International Herpesvirus Workshop - GlobeNewsWire
- 10 months ago - Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus Helicase-Primase Inhibitor Candidate ABI-5366 - GlobeNewsWire
- 11 months ago - Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congress™ 2024 - GlobeNewsWire
- 11 months ago - Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights - GlobeNewsWire